| Indication | Multiple Sclerosis |
| Status | – Exclusive License Agreement with Cycle Pharmaceuticals Ltd. for Commercialization of Tascenso ODT in the USA on March 4th, 2022. – Final Approval of Tascenso ODT, 0.25mg Granted on December 23th, 2021. – Tentative Approval of Tascenso ODT, 0.5mg Granted on October 18th, 2021. |
| Product Advantages | Orally disintegrating tablet format is generally known to be of particular relevance to patients with swallowing difficulties. Handa ODT product is relevant to patients who have some level of dysphagia, patients who need to switch therapies due to efficacy or tolerability issues with current therapy, and patients who prefer ODT administration. |
| Potential Market | Currently, there are no orally disintegrating tablet for Multiple Sclerosis-targeted on the market. |
?
R&D
Tascenso ODT
